Back to speakers

Richard MOREAU

Senior Scientist, Directeur de Recherche de Classe Exceptionnelle (DRCE) à l'INSERM (French NIH)


City: Paris

Institution: UMR_S 1149, Centre de Recherche sur l’Inflammation CRI


Biography of Richard MOREAU

Dr. Richard Moreau, Senior Scientist, Vice-Chairman of the Center for Research on Inflammation, INSERM, Paris Diderot University and Cnrs, Paris, France

Dr. Richard Moreau is: 1) Senior Scientist (Outstanding Grade) at the French NIH (INSERM); 2) Vice-Chairman of the Centre of Research on Inflammation (CRI, Paris, France), endorsed by the French NIH (INSERM), Paris Diderot University, and Cnrs; 3) Consultant in Hepatology at the Liver Unit at Beaujon Hospital, Assistance Publique Hôpitaux de Paris, Clichy, France; 4) Adjunct Professor at the Institute of Liver and Biliary Sciences (ILBS), New Delhi, India; 5) Advisor for Hepatology at the INSERM’ Institute “Pathophysiology, Metabolism, Nutrition”; 6) Deputy Director of the Grifols Chair for Translational Research at the European Foundation for the Study of Chronic Liver Failure (EF Clif), Barcelona, Spain.

His main research interest is pathophysiology and treatment of complications of cirrhosis, in particular acute-on-chronic liver failure (ACLF). He was responsible for the fact that France was the first country in the world to approve terlipressin as a first-line treatment for hepatorenal syndrome. Because of his interest for end-stage liver disease. In 2009, he was among founding members of the EASL-Chronic Liver Failure (CLIF) Consortium which includes now 90 European Centers and is dedicated to develop research on cirrhosis. He was PI of the first study (called CANONIC study) performed under the umbrella of the EASL-CLIF Consortium; this study was the first to provide an evidence-based definition for ACLF.

He is now Senior Editor of Journal of Hepatology (2015-19). He has been Associate Editor for Journal of Hepatology (2010-14) and Liver International (2007-9).

His scientific production consists of 318 Peer-Reviewed publications (PubMed, November 2017), of which 222 Original Articles, 96 Review Articles or Editorials; his h-index is of 63; his SIGAPS score (French score) is 4497.

He was Editor of 1 book and 34 book chapters

He gave 242 Invited lectures (70% outside France), 300 communications in International meetings.

PHC's participations

12th PHC – 2019

Monday, January 14th 2019

LUNCH WORKSHOPS - 4-Management of difficult ascitis: Room 243 (chairman)

Tuesday, January 15th 2019


11th PHC – 2018

Tuesday, January 16th 2018


10th PHC – 2017

Tuesday, January 31st 2017


8th PHC – 2015

Tuesday, January 13th 2015

End-stage liver disease is a multifaceted condition (chairman)

9th PHC – 2016

Tuesday, January 12th 2016

End-stage liver disease is a multifaceted condition (chairman)